Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeloxiri Salvage Therapy in Refractory Metastatic Colorectal Cancer
NCT03146377Phase 2Completed
- Sponsor
- The University of Hong Kong
- Start
- Apr 2014
- Primary completion
- Dec 2016
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC), sponsored by The University of Hong Kong. Primary endpoint: Objective Response Rate at 12 months. Started Apr 2014; status: completed.
02
Drugs
capecitabineoxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03146377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03146377.